Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Total Current Liabilities (2016 - 2025)

Marimed (MRMD) has disclosed Total Current Liabilities for 15 consecutive years, with $59.1 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities rose 18.12% to $59.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $59.1 million through Dec 2025, up 18.12% year-over-year, with the annual reading at $59.1 million for FY2025, 18.12% up from the prior year.
  • Total Current Liabilities for Q4 2025 was $59.1 million at Marimed, up from $56.6 million in the prior quarter.
  • The five-year high for Total Current Liabilities was $59.1 million in Q4 2025, with the low at $14.6 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $35.4 million, with a median of $32.5 million recorded in 2022.
  • The sharpest move saw Total Current Liabilities plummeted 58.01% in 2021, then skyrocketed 134.89% in 2022.
  • Over 5 years, Total Current Liabilities stood at $27.2 million in 2021, then fell by 2.69% to $26.5 million in 2022, then grew by 16.5% to $30.9 million in 2023, then surged by 62.03% to $50.0 million in 2024, then increased by 18.12% to $59.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $59.1 million, $56.6 million, and $50.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.